HUP9902460A2 - Új helyettesített imidazolszármazékok, alkalmazásuk, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Új helyettesített imidazolszármazékok, alkalmazásuk, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9902460A2
HUP9902460A2 HU9902460A HUP9902460A HUP9902460A2 HU P9902460 A2 HUP9902460 A2 HU P9902460A2 HU 9902460 A HU9902460 A HU 9902460A HU P9902460 A HUP9902460 A HU P9902460A HU P9902460 A2 HUP9902460 A2 HU P9902460A2
Authority
HU
Hungary
Prior art keywords
cr10r20
alkyl
heterocyclic
nr13r14
substituted
Prior art date
Application number
HU9902460A
Other languages
English (en)
Inventor
Jerry L. Adams
Jeffrey C. Boehm
Dennis Lee
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of HUP9902460A2 publication Critical patent/HUP9902460A2/hu
Publication of HUP9902460A3 publication Critical patent/HUP9902460A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

A találmány a gyógyászatban citőkin inhibitőrőkként felhasználható (I)általánős képletű vegyületekre és az ezeket tartalmazógyógyszerkészítményekre vőnatkőzik, ahől a képletben R1 4-piridil-,pirimidinil-, kinőlil-, izőkinőlil-, 4-kinazőlinil-, 1-imidazőlil-vagy 1-benzimidazőlilcsőpőrt, ahől a heterőaril-gyűrű -YRa általánősképletű csőpőrttal és adőtt esetben tővábbi helyettesítővelszűbsztitűált; Y jelentése őxigén- vagy kénatőm; Ra adőtt esetbenszűbsztitűált aril-, aril-alkil-, heterőciklűsős, heterőciklűsőscsőpőrttal szűbsztitűált alkil-, heterőaril- vagy heterőaril-alkil-csőpőrt; Rb hidrőgénatőm, alkil-, ciklőalkil-, aril-, aril-alkil-,heterőciklűsős, heterőciklűsős csőpőrttal szűbsztitűált alkil-,heterőaril- vagy heterőaril-alkil-csőpőrt; R4 fenil-, 1-naftil-, 2-naftil- vagy heterőarilcsőpőrt, amelyek bármelyike adőtt esetbenegyszeresen vagy kétszeresen szűbsztitűált, ahől a szűbsztitűensekegymástól függetlenek és egy 4-fenil-, 4-naft-1-il-, 5-naft-2-il- vagy6-naft-2-il-szűbsztitűens halőgénatőm, cianő-, nitrőcsőpőrt, -C(Z)NR7R17, -C(Z)OR16, -(CR10R20)vCOR12, -SR5, -SOR5, -OR12, adőttesetben halőgénatőmmal szűbsztitűált alkilcsőpőrt, -ZC(Z)R12, -NR10C(Z)R16 vagy -(CR10R20)vNR10R20, míg az egyéb pőzíciókban lévőszűbsztitűens halőgénatőm, cianőcsőpőrt, -C(Z)nR13R14, -C(Z)OR3, -(CR10R20)m''COR3, -S(O)mR3, -OR3, adőtt esetben halőgénatőmszűbsztitűált alkilcsőpőrt, -(CR10R20)m''NR10C(Z)R3, -NR10S(O)m'R8, -NR10S(O)m'NR7R17, -ZC(Z)R3 vagy -(CR10R20)m''NR13R14; v 0, 1 vagy 2; m0, 1 vagy 2; m' 1 vagy 2; m'' 0, 1, 2, 3, 4 vagy 5; R2 -(CR10R20)n'OR9, heterőciklűsős csőpőrt, adőtt esetben heterőciklűsőscsőpőrttal szűbsztitűált alkilcsőpőrt, halőgén-alkil-, alkenil-,alkinil-, ciklőalkil-, ciklőalkil-alkil-, ciklőalkenil-, ciklőalkenil-alkil-, aril-, aril-alkil-, heterőaril-, heterőaril-alkil-, -(CR10R20)nOR11, -(CR10R20)nS(O)mR18, -(CR10R20)nNHS(O)2R18, -(CR10R20)nNR13R14, -(CR10R20)nNO2, -(CR10R20)nCN, -(CR10R20)nSO2R18, -(CR10R20)nS(O)m'NR13R14, -(CR10R20)nC(Z)R11, -(CR10R20)nOC(Z)R11, -(CR10R20)nC(Z)OR11, -(CR10R20)nC(Z)NR13R14, -(CR10R20)nC(Z)NR11OR9, -(CR10R20)nNR10C(Z)R11, -(CR10R20)nNR10C(Z)N13R14, -(CR10R20)nN(OR6)C(Z)NR13R14, -(CR10R20)nN(OR6)C(Z)R11, -(CR10R20)nC(=NOR6)R11, -(CR10R20)nNR10C=NR19)NR13R14, -(CR10R20)nOC(Z)NR13R14, -(CR10R20)nNR10C(Z)NR13R14, -(CR10R20)nNR10C(Z)OR10, 5-(R18)-1,2,4-őxadiazől-3-il- vagy 4-(R12)-5-(R18R19)-4,5-dihidrő- 1,2,4-őxadiazől-3-il-csőpőrt; n 1, 2, 3, 4, 5,6, 7, 8, 9 vagy 10; n' 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 vagy 10; Z őxigén-vagy kénatőm; R3 heterőciklűsős vagy heterőciklűsős csőpőrttalszűbsztitűált alkilcsőpőrt vagy R8; R5 hidrőgénatőm, alkil-, alkenil-,alkinilcsőpőrt vagy -NR7R17; R6 hidrőgénatőm, katiőn, alkil-,ciklőalkil-, aril-, aril-alkil-, heterőaril-, heterő
HU9902460A 1996-01-11 1997-01-10 Novel substituted imidazole compounds, their use, method for their preparation and pharmaceutical compositions containing them HUP9902460A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US990796P 1996-01-11 1996-01-11
US1495296P 1996-04-05 1996-04-05

Publications (2)

Publication Number Publication Date
HUP9902460A2 true HUP9902460A2 (hu) 1999-11-29
HUP9902460A3 HUP9902460A3 (en) 2000-03-28

Family

ID=26680002

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902460A HUP9902460A3 (en) 1996-01-11 1997-01-10 Novel substituted imidazole compounds, their use, method for their preparation and pharmaceutical compositions containing them

Country Status (21)

Country Link
US (3) US5977103A (hu)
EP (1) EP0900083B1 (hu)
JP (1) JP2000503302A (hu)
KR (1) KR19990077164A (hu)
CN (1) CN1213306A (hu)
AT (1) ATE247470T1 (hu)
AU (1) AU715900B2 (hu)
BR (1) BR9706973A (hu)
CA (1) CA2242327A1 (hu)
CZ (1) CZ216498A3 (hu)
DE (1) DE69724246T2 (hu)
ES (1) ES2205167T3 (hu)
HU (1) HUP9902460A3 (hu)
IL (1) IL125223A0 (hu)
MX (1) MX9805631A (hu)
NO (1) NO983189L (hu)
NZ (1) NZ327044A (hu)
PL (1) PL187516B1 (hu)
TR (1) TR199801361T2 (hu)
TW (1) TW505637B (hu)
WO (1) WO1997025045A1 (hu)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
US6046208A (en) * 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5977103A (en) * 1996-01-11 1999-11-02 Smithkline Beecham Corporation Substituted imidazole compounds
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
EP0889888A4 (en) * 1996-03-25 2003-01-08 Smithkline Beecham Corp NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
WO1998007425A1 (en) 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5929076A (en) * 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
JP2002504909A (ja) 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション 新規な置換ピラゾールおよびピラゾリン化合物
US6610695B1 (en) 1997-06-19 2003-08-26 Smithkline Beecham Corporation Aryloxy substituted pyrimidine imidazole compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
AU8381098A (en) 1997-07-02 1999-01-25 Smithkline Beecham Corporation Novel cycloalkyl substituted imidazoles
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
JP2001518507A (ja) 1997-10-08 2001-10-16 スミスクライン・ビーチャム・コーポレイション 新規シクロアルケニル置換化合物
AU9449398A (en) * 1997-10-10 1999-05-03 Imperial College Innovations Ltd. Use of csaidtm compounds for the management of uterine contractions
JPH11193281A (ja) * 1997-10-27 1999-07-21 Takeda Chem Ind Ltd アデノシンａ３受容体拮抗剤およびチアゾール化合物
US6335340B1 (en) 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
US6172106B1 (en) 1998-02-09 2001-01-09 R. Armour Forse Sesamol inhibition of Δ-5-desaturase activity and uses therefor
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
WO1999064069A1 (en) * 1998-06-10 1999-12-16 Ophidian Pharmaceuticals, Inc. Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
ES2221426T3 (es) 1998-08-20 2004-12-16 Smithkline Beecham Corporation Nuevos compuestos de triazol sustituidos.
WO2000026209A1 (en) * 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
ATE258055T1 (de) * 1998-11-04 2004-02-15 Smithkline Beecham Corp Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
US6239279B1 (en) * 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
ATE387448T1 (de) 1998-12-17 2008-03-15 Hoffmann La Roche 4,5-pyrazinoxindole als proteinkinasehemmer
US6288089B1 (en) * 1998-12-21 2001-09-11 Michael Zawada Use of kinase inhibitors for treating neurodegenerative diseases
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US7122666B2 (en) * 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
JP2003528043A (ja) 1999-11-23 2003-09-24 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４‐ジヒドロ−（１Ｈ）キナゾリン−２−オン化合物
US7053098B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-Dihydro-(1H) quinazolin-2-one compounds as CSBP/P38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
ATE281439T1 (de) 1999-11-23 2004-11-15 Smithkline Beecham Corp 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
SK12672001A3 (sk) * 1999-12-08 2002-04-04 Pharmacia Corporation Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JP2004503601A (ja) * 2000-07-13 2004-02-05 ファルマシア・コーポレーション 眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
CA2426654C (en) * 2000-10-23 2010-12-21 Smithkline Beecham Corporation 2,4,8-trisubstituted-8h-pyrido[2,3-d}pyrimidin-7-one compounds
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
AP2002002463A0 (en) 2001-03-09 2002-06-30 Pfizer Prod Inc Novel triazolo-pyrimides anti-inflammatory compounds.
BR0207957A (pt) * 2001-03-09 2004-02-25 Pfizer Prod Inc Compostos antiinflamatórios de benzimidazol
MY137736A (en) 2001-04-03 2009-03-31 Pharmacia Corp Reconstitutable parenteral composition
DE60205974T2 (de) * 2001-04-04 2006-06-29 Pfizer Products Inc., Groton Neue Benzotriazole mit entzündungshemmender Wirkung
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
GB0124941D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124934D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
MXPA04007838A (es) 2002-02-12 2004-10-15 Smithkline Beecham Corp Derivados de nicotamida utiles como inhibidores p38.
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
RS92004A (en) 2002-04-23 2006-12-15 Bristol-Myers Squibb Company Pyrrolo-triazine aniline compounds useful as kinase inhibitors
EP1534282B1 (en) 2002-07-09 2006-12-27 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
EP1554272B1 (en) 2002-08-09 2006-10-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
JP2006508914A (ja) * 2002-08-30 2006-03-16 ファイザー・プロダクツ・インク トリアゾロ−ピリジン製造のための新規な方法および中間体
US7037923B2 (en) * 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7005523B2 (en) * 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
PA8579601A1 (es) * 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US20040092547A1 (en) * 2002-08-30 2004-05-13 Pfizer Inc Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US6949652B2 (en) * 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
US20080039461A1 (en) * 2002-09-05 2008-02-14 Protter Andrew A Treatment of pain by inhibition of p38 map kinase
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
UA80296C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
AU2003291227A1 (en) 2002-11-05 2004-06-07 Smithkline Beecham Corporation Antibacterial agents
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
GB0308186D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) * 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
DK1534305T3 (da) 2003-05-07 2007-02-05 Osteologix As Behandling af brusk-/knoglelidelser med vandoplöselige strontiumsalte
BRPI0410905A (pt) * 2003-06-03 2006-06-27 Novartis Ag inibidores de p-38
CA2526455C (en) 2003-06-26 2012-10-09 Novartis Ag 5-membered heterocycle-based p38 kinase inhibitors
MXPA06000915A (es) 2003-07-25 2006-03-30 Novartis Ag Inhibidores de quinasa p-38.
GB0318814D0 (en) * 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
US7419978B2 (en) * 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
US20060052390A1 (en) * 2003-12-24 2006-03-09 Scios, Inc. Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
US20060079461A1 (en) * 2003-12-24 2006-04-13 Scios, Inc. Treatment of multiple myeloma by inhibition of p38 MAP kinase
GB0402143D0 (en) * 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
US7863310B2 (en) 2004-02-03 2011-01-04 Eli Lilly And Company Kinase inhibitors
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060421A1 (es) 2004-08-12 2006-06-01 Bristol Myers Squibb Co Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa
US20080051416A1 (en) * 2004-10-05 2008-02-28 Smithkline Beecham Corporation Novel Compounds
US20060106288A1 (en) 2004-11-17 2006-05-18 Roth Alex T Remote tissue retraction device
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
US20060178388A1 (en) * 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
MX2007012951A (es) * 2005-03-25 2008-01-11 Glaxo Group Ltd Procedimiento para preparar derivados de pirido[2,3-d] pirimidin-7-ona y 3,4-dihidropirimidino[4,5-d]pirimidin-2(1h)-ona.
US20060235020A1 (en) * 2005-04-18 2006-10-19 Soojin Kim Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
GB0512429D0 (en) * 2005-06-17 2005-07-27 Smithkline Beecham Corp Novel compound
US7473784B2 (en) 2005-08-01 2009-01-06 Bristol-Myers Squibb Company Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
WO2007049820A1 (ja) 2005-10-28 2007-05-03 Takeda Pharmaceutical Company Limited 複素環アミド化合物及びその用途
EA200801945A1 (ru) * 2006-03-07 2009-02-27 Бристол-Маерс Сквибб Компани Пирролотриазинанилиновые пролекарственные соединения, полезные в качестве ингибиторов киназы
WO2008057775A2 (en) 2006-10-27 2008-05-15 Bristol-Myers Squibb Company Heterocyclic amide compounds useful as kinase inhibitors
US7943617B2 (en) * 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
US20100111858A1 (en) * 2007-01-19 2010-05-06 Howard Carol P Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands
AU2008240279A1 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of TNFa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
KR101012313B1 (ko) * 2008-06-10 2011-02-09 서울대학교산학협력단 염증질환 치료제
WO2009155388A1 (en) 2008-06-20 2009-12-23 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
US8410128B2 (en) * 2008-06-20 2013-04-02 Bristol-Myers Squibb Company Triazolopyridine compounds useful as kinase inhibitors
MX2012003693A (es) * 2009-10-01 2012-04-19 Alcon Res Ltd Composiciones de olopatadine y usos de las mismas.
WO2012031057A1 (en) 2010-09-01 2012-03-08 Bristol-Myers Squibb Company Bms- 582949 for the treatment of resistant rheumatic disease
WO2022195579A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2748119A (en) * 1954-06-23 1956-05-29 Searle & Co 6-furyl and 6-thienyl derivatives of 4-trifluoromethyl-2-pyrimidinamines
US3557114A (en) * 1968-12-23 1971-01-19 Merck & Co Inc 1-substituted-3-(2-pyrimidinyl) imidazolium salts
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3940486A (en) * 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
US4058614A (en) * 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) * 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
GR75287B (hu) * 1980-07-25 1984-07-13 Ciba Geigy Ag
US4503065A (en) * 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
US4565875A (en) * 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4686231A (en) * 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467A0 (en) * 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
WO1992010498A1 (en) * 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
AU9137591A (en) * 1990-12-13 1992-07-08 Smithkline Beecham Corporation Novel csaids
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
MX9300141A (es) * 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5593991A (en) * 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
CA2148931A1 (en) * 1993-10-01 1995-04-13 Jurg Zimmermann Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
PL179417B1 (en) * 1993-10-01 2000-09-29 Novartis Ag Pharmacologically active derivatives of pyridine and methods of obtaining them
PT672042E (pt) * 1993-10-01 2006-08-31 Novartis Ag Derivados de pirimidinoamina farmacologicamente activos e processos para a sua preparacao
NZ302117A (en) * 1995-01-12 1999-10-28 Smithkline Beecham Corp 1-cycloalkyl or cycloalkylalkyl 4,5-trisubstituted imidazole derivatives and medicaments
US5658903A (en) * 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
US5739143A (en) * 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
JP2001508395A (ja) * 1996-01-11 2001-06-26 スミスクライン・ビーチャム・コーポレイション 新規シクロアルキル置換イミダゾール
AP9700912A0 (en) * 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
ZA97175B (en) * 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US5977103A (en) * 1996-01-11 1999-11-02 Smithkline Beecham Corporation Substituted imidazole compounds
EP0889888A4 (en) * 1996-03-25 2003-01-08 Smithkline Beecham Corp NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
US6235760B1 (en) * 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
WO1998007425A1 (en) * 1996-08-21 1998-02-26 Smithkline Beecham Corporation Imidazole compounds, compositions and use
WO1998022109A1 (en) * 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles as glucagon antagonists

Also Published As

Publication number Publication date
NZ327044A (en) 2000-01-28
WO1997025045A1 (en) 1997-07-17
EP0900083A4 (en) 1999-08-25
HUP9902460A3 (en) 2000-03-28
KR19990077164A (ko) 1999-10-25
NO983189L (no) 1998-09-10
CA2242327A1 (en) 1997-07-17
US5977103A (en) 1999-11-02
CZ216498A3 (cs) 1999-08-11
TR199801361T2 (xx) 1998-10-21
ATE247470T1 (de) 2003-09-15
MX9805631A (es) 1998-11-30
DE69724246T2 (de) 2004-06-03
EP0900083A1 (en) 1999-03-10
PL187516B1 (pl) 2004-07-30
BR9706973A (pt) 1999-04-06
CN1213306A (zh) 1999-04-07
AU715900B2 (en) 2000-02-10
PL327735A1 (en) 1998-12-21
EP0900083B1 (en) 2003-08-20
US5864036A (en) 1999-01-26
US5756499A (en) 1998-05-26
JP2000503302A (ja) 2000-03-21
ES2205167T3 (es) 2004-05-01
TW505637B (en) 2002-10-11
IL125223A0 (en) 1999-03-12
AU1577497A (en) 1997-08-01
DE69724246D1 (de) 2003-09-25

Similar Documents

Publication Publication Date Title
HUP9902460A2 (hu) Új helyettesített imidazolszármazékok, alkalmazásuk, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP9802259A2 (hu) 1,4,5-Helyettesített imidazolszármazékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
AR012567A1 (es) Derivados de imidazol y procedimiento para su preparacion
HUP9900645A2 (hu) Új, helyettesített imidazolvegyületek, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
CO5370680A1 (es) Nuevos compuestos
RU2403253C2 (ru) Пуриновые производные для применения в качестве агонистов аденозинового рецептора а-2а
HUP9901233A2 (hu) Cikloalkil-szubsztituált imidazolok
HUP0001540A2 (hu) Fungicid és artropodicid hatású metil-szubsztituált fenilszármazékok, és alkalmazásuk
CA2684105A1 (en) Pyridine derivatives
TW330934B (en) Novel 1,4,5-substituted imidazole compounds and processes for the preparation thereof and pharmaceutical composition for use in inhibiting cytokine mediated diseases
HUP0400266A2 (hu) Imidazo[1,2-a]piridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk herpeszvírus-fertőzések megelőzésére vagy kezelésére
HUP0300350A2 (hu) Új 3-amino-azetidin-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
AP2002002460A0 (en) Novel benzimidazole anti-inflammatory compounds.
ATE448252T1 (de) Neue trifunktionelle photoinitiatoren
TW200613297A (en) Pyrazole derivatives
DE60320012D1 (de) Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen
BR0201087A (pt) Compostos antiinflamatórios de benzotriazol
AR040031A1 (es) Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen
EA201070782A1 (ru) Производные оксадиазола, активные в отношении сфингозин-1-фосфата(sip)
HUP0300190A2 (en) Tricyclic compounds as hiv reverse transcriptase inhibitors and pharmaceutical compositions containing them and their preparation
CA2487805A1 (en) Peptide deformylase inhibitors
ES8800175A1 (es) Procedimiento para la obtencion de derivados de acido 5-(azoli-loxifenilcarbamoil)-barbiturico.
DE60201089D1 (de) 6-(2-chlor-6-fluor-phenyl)-triazolpyrimidine
BRPI0417928A (pt) composto, composição farmacêutica, métodos para o tratamento ou a prevenção de uma condição mediada pelo receptor de bradicinina b1, e de dor em um mamìfero, e, uso de um composto
RU2012134463A (ru) Производные гетероциклических карбоновых кислот, содежащие 2,5,7-замещенное оксазолопиримидиновое в кольцо

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal